Biotech IV Monitor

HALO — Halozyme Therapeutics Inc.

$9.7B market cap · 1 upcoming readout tracked

Clinical trial readout dates for Halozyme Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2028.

Next readoutMarch 2028in ~16 months
Upcoming readouts11 Phase 3
Market cap$9.7B
Cash & investments$1.03Bas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-05

Upcoming readouts

Phase 3 Testosterone enanthate
Hypogonadism, Male · NCT06689085
March 2028
Recruiting

Cash position

Halozyme Therapeutics Inc. reported $1.03B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). It reported net income of $247M for that quarter.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-05

Companies working on similar indications

Discussion

No messages yet. If you follow HALO, you can start the conversation.
Track HALO in real time
See live implied volatility for HALO and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on HALO
Contact — questions or corrections about HALO: dukeupt@gmail.com